Andreessen Horowitz Funds Sell $11.75M in Nautilus Biotechnology Stock
Summary
Andreessen Horowitz funds, including Marc Andreessen and Benjamin Horowitz, sold 5 million shares of Nautilus Biotechnology for $11.75 million, significantly reducing their stake.
Key Events
-
Significant Share Sale by Andreessen Horowitz
AH Bio Fund II and AH LSV II sold a combined 5,000,000 shares of common stock on June 2, 2026.
-
$11.75 Million Transaction Value
The shares were sold in a single block trade at $2.35 per share, totaling $11,750,000.
-
Reduced Stake to 9.9%
Following the sale, Marc Andreessen and Benjamin Horowitz, through their associated funds, beneficially own 12,653,917 shares, representing 9.9% of the outstanding common stock.
-
Substantial Reduction of Holdings
The sale represents a reduction of approximately 28.32% of their previous total holdings in the company.
Analysis
Andreessen Horowitz (a16z) funds, including those associated with Marc Andreessen and Benjamin Horowitz, sold 5 million shares of Nautilus Biotechnology common stock for $11.75 million. This sale represents a significant reduction of their stake, accounting for 3.45% of the company's market capitalization and over 28% of their previous holdings. This substantial divestment by a prominent venture capital firm, especially following recent positive news about the Voyager Platform and improved financials, could be interpreted negatively by the market.
At the time of this filing, NAUT was trading at $2.68 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $340.6M. The 52-week trading range was $0.62 to $4.31. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.